Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

W. Scheithauer · SciRah

Researcher profile · Semantic Scholar

W. Scheithauer

Share profile

W. Scheithauer — researcher profile on SciRah

h-index: 67
Works: 402
Citations: 25K

Most-cited papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
V. Heinemann, L. V. von Weikersthal, T. Decker, A. Kiani +23 more
2014The Lancet Oncology1,660 citations
Semantic Scholar
Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study
L. Saltz, S. Clarke, E. Díaz-Rubio, W. Scheithauer +9 more
2023Journal of Clinical Oncology1,059 citations
Semantic Scholar
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
D. Goldstein, R. El-Maraghi, P. Hammel, V. Heinemann +13 more
2015Journal of the National Cancer Institute630 citations
Semantic Scholar
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
T. André, A. de Gramont, D. Vernerey, B. Chibaudel +21 more
2015Journal of Clinical Oncology627 citations
Semantic Scholar
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
S. Stintzing, D. Modest, Lisa Rossius, M. Lerch +19 more
2016The Lancet Oncology390 citations
Semantic Scholar
Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality
N. Pavo, M. Raderer, M. Hülsmann, S. Neuhold +18 more
2015Heart237 citations Open access
Semantic Scholar
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial
V. Heinemann, L. V. von Weikersthal, T. Decker, A. Kiani +15 more
2020British Journal of Cancer140 citations Open access
Semantic Scholar
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
J. Tabernero, E. Chiorean, J. Infante, S. Hingorani +9 more
2015The Oncologist136 citations Open access
Semantic Scholar
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer.
D. Modest, S. Stintzing, L. V. von Weikersthal, T. Decker +15 more
2015Journal of Clinical Oncology129 citations Open access
Semantic Scholar
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
C. Tournigand, B. Chibaudel, B. Samson, W. Scheithauer +17 more
2015The Lancet Oncology122 citations
Semantic Scholar
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
S. Stintzing, P. Wirapati, H. Lenz, D. Neureiter +16 more
2017115 citations Open access
Semantic Scholar
MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside.
B. Wittig, M. Schmidt, W. Scheithauer, H. Schmoll
2015Critical reviews in oncology/hematology80 citations Open access
Semantic Scholar
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease
E. ter Veer, L. V. van Rijssen, M. Besselink, R. Mali +29 more
2018The Lancet Oncology65 citations Open access
Semantic Scholar
Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial.
W. Scheithauer, R. Ramanathan, M. Moore, T. Macarulla +7 more
2016Journal of Gastrointestinal Oncology62 citations Open access
Semantic Scholar
Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.
V. Heinemann, D. Modest, L. V. von Weikersthal, T. Decker +15 more
201456 citations
Semantic Scholar
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
G. Prager, Kira Braemswig, A. Martel, M. Unseld +5 more
2014Cancer Science54 citations Open access
Semantic Scholar
Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306)
D. Modest, S. Stintzing, L. V. von Weikersthal, T. Decker +13 more
2017OncoTarget46 citations Open access
Semantic Scholar
A real-world analysis of second-line treatment options in pancreatic cancer: liposomal-irinotecan plus 5-fluorouracil and folinic acid
M. Kieler, M. Unseld, Daniela Bianconi, W. Scheithauer +1 more
2019Therapeutic Advances in Medical Oncology45 citations Open access
Semantic Scholar
Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.
D. Goldstein, Robert Hassan El Maraghi, P. Hammel, V. Heinemann +13 more
201440 citations
Semantic Scholar
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
M. Michl, S. Stintzing, L. V. von Weikersthal, T. Decker +18 more
2016Annals of Oncology31 citations Open access
Semantic Scholar
Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
M. Kieler, M. Unseld, Daniela Bianconi, M. Schindl +3 more
2020Journal of Clinical Medicine30 citations Open access
Semantic Scholar
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
T. André, D. Vernerey, S. Im, G. Bodoky +17 more
2019Annals of Oncology28 citations Open access
Semantic Scholar
Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer
F. Moik, F. Posch, E. Grilz, W. Scheithauer +3 more
2020Thrombosis Research27 citations Open access
Semantic Scholar
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial.
A. Stahler, S. Stintzing, J. V. von Einem, C. Westphalen +16 more
2020European Journal of Cancer23 citations
Semantic Scholar
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: a subgroup analysis of the Western European cohort of the MPACT trial
J. Tabernero, V. Kunzmann, W. Scheithauer, M. Reni +3 more
2017OncoTargets and Therapy23 citations Open access
Semantic Scholar
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
A. Sobrero, H. Lenz, C. Eng, W. Scheithauer +5 more
2020The Oncologist20 citations Open access
Semantic Scholar
Relation of early tumor shrinkage (ETS) observed in first‐line treatment to efficacy parameters of subsequent treatment in FIRE‐3 (AIOKRK0306)
D. Modest, S. Stintzing, Ludwig Fischer von Weikersthal, T. Decker +16 more
2017International Journal of Cancer20 citations Open access
Semantic Scholar
Integrin beta-3 genetic variants and risk of venous thromboembolism in colorectal cancer patients
Daniela Bianconi, Alexandra Schüler, C. Pausz, A. Geroldinger +8 more
2015Thrombosis Research20 citations Open access
Semantic Scholar
Optimizing Treatment Sequence for Late‐line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib
M. Unseld, Magdalena Drimmel, A. Siebenhüner, A. Gleiss +5 more
2018Clinical colorectal cancer19 citations
Semantic Scholar
Subclinical involvement of the liver is associated with prognosis in treatment naïve cancer patients
N. Pavo, M. Raderer, G. Goliasch, R. Wurm +19 more
2017OncoTarget18 citations Open access
Semantic Scholar
Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first‐line treatment within the randomized Phase III trial FIRE‐3 (AIO KRK‐0306)
Lian Liu, N. Erickson, I. Ricard, L. V. von Weikersthal +19 more
2021International Journal of Cancer17 citations Open access
Semantic Scholar
Clinical Benefit Response in Pancreatic Cancer Trials Revisited
J. Bernhard, D. Dietrich, B. Glimelius, G. Bodoky +2 more
2014Oncology Research and Treatment17 citations Open access
Semantic Scholar
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
L. Fischer, S. Stintzing, L. V. von Weikersthal, D. Modest +22 more
2022British Journal of Cancer16 citations Open access
Semantic Scholar
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
J. Holch, I. Ricard, S. Stintzing, L. V. von Weikersthal +14 more
2019European Journal of Cancer16 citations
Semantic Scholar
Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma.
W. Scheithauer, G. Kornek, G. Prager, Nadja Stranzl +6 more
2016Journal of Gastrointestinal Oncology16 citations
Semantic Scholar
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
P. Gargiulo, D. Dietrich, R. Herrmann, G. Bodoky +6 more
2019Therapeutic Advances in Medical Oncology15 citations Open access
Semantic Scholar
Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).
V. Heinemann, N. Kraemer, H. Buchner, L. V. von Weikersthal +16 more
201815 citations
Semantic Scholar
Relevance of liver‐limited disease in metastatic colorectal cancer: Subgroup findings of the FIRE‐3/AIO KRK0306 trial
J. Holch, I. Ricard, S. Stintzing, Ludwig Fischer von Weikersthal +22 more
2018International Journal of Cancer15 citations Open access
Semantic Scholar
Clinical pharmacokinetics of capecitabine and its metabolites in combination with the monoclonal antibody bevacizumab.
André Farkouh, W. Scheithauer, P. Buchner, A. Georgopoulos +3 more
2014Anticancer Research14 citations
Semantic Scholar
Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression
T. Fuereder, J. Stift, I. Kuehrer, Nadja Stranzl +3 more
2014European Journal of Clinical Investigation13 citations
Semantic Scholar
Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease
M. Kieler, W. Scheithauer, C. Zielinski, A. Chott +2 more
2016ESMO Open11 citations Open access
Semantic Scholar
Nab-paclitaxel as alternative treatment regimen in advanced cholangiocellular carcinoma.
M. Unseld, W. Scheithauer, Roman Weigl, G. Kornek +6 more
2016Journal of Gastrointestinal Oncology10 citations Open access
Semantic Scholar
Real-world dosing of regorafenib in metastatic colorectal cancer (mCRC): Interim analysis from the prospective, observational CORRELATE study.
Manuel O'Connor Juan, L. Öhler, W. Scheithauer, J. Metges +12 more
2017Annals of Oncology9 citations Open access
Semantic Scholar
IMPALA, a randomized phase III study in patients with metastatic colorectal carcinoma: Immunomodulatory maintenance therapy with TLR-9 agonist MGN1703.
D. Cunningham, A. Zurlo, R. Salazar, M. Ducreux +7 more
20159 citations
Semantic Scholar
Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306).
D. Modest, I. Ricard, S. Stintzing, L. V. von Weikersthal +15 more
2017European Journal of Cancer8 citations
Semantic Scholar
Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306).
D. Modest, S. Stintzing, L. V. von Weikersthal, T. Decker +14 more
20177 citations
Semantic Scholar
Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival.
H. Schmoll, J. Riera-Knorrenschild, H. Kopp, F. Mayer +9 more
20157 citations
Semantic Scholar
Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial
D. Cunningham, R. Salazar, A. Sobrero, M. Ducreux +9 more
2019Annals of Oncology6 citations Open access
Semantic Scholar
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
W. Scheithauer, P. Putora, B. Grünberger, W. Eisterer +5 more
2019Therapeutic Advances in Gastroenterology6 citations Open access
Semantic Scholar
Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel
Daniela Bianconi, G. Heller, Daniel Spies, M. Herac +8 more
2017Scientific Reports6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

V. Heinemann×19
Invite
V. Heinemann — researcher profile on SciRah
T. Decker×17
Invite
T. Decker — researcher profile on SciRah
A. Kiani×17
Invite
A. Kiani — researcher profile on SciRah
T. Heintges×17
Invite
T. Heintges — researcher profile on SciRah

×17

Invite

C. Kahl — researcher profile on SciRah

Invite

D. Modest — researcher profile on SciRah

S. Stintzing×17

Invite

S. Stintzing — researcher profile on SciRah

F. Kullmann×16

Invite

F. Kullmann — researcher profile on SciRah

L. V. von Weikersthal×15

Invite

L. V. von Weikersthal — researcher profile on SciRah

U. Vehling-Kaiser×13

Invite

U. Vehling-Kaiser — researcher profile on SciRah

S. Al-Batran×13

Invite

S. Al-Batran — researcher profile on SciRah

T. Kirchner×13

Invite

T. Kirchner — researcher profile on SciRah